The Biologics News and Reports Portal

Show Cart

La Merie Publishing

Results 81 - 100 of 194

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

150.00 €

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

400.00 €

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

70.00 €

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

200.00 €

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Dec 2016 Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

800.00 €

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

1,140.00 €

1,900.00 €

(Discount: 40.00%)

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

700.00 €

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

200.00 €

Sep 2016 Competitor Analysis Immunotoxins 2016

200.00 €

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

3,000.00 €

4,500.00 €

(Discount: 33.33%)

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

700.00 €

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

500.00 €

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

2,450.00 €

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

250.00 €

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

3,100.00 €

6,200.00 €

(Discount: 50.00%)

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

500.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

300.00 €

Shopping cart

Cart empty

Shopping cart

Cart empty

Latest report

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Featured Products

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

La Merie Publishing

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Dec 2016 Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

Sep 2016 Competitor Analysis Immunotoxins 2016

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing